A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention

To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with chronic migraine. 

Principal Investigator

CONTACT INFORMATION

Primary Contact:
Maria Coburn
(650) 736-9551